Clinical

Dataset Information

0

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only


ABSTRACT: In this Phase II study the investigators plan to determine the overall response rate (ORR) of the combination of FOLFOXIRI plus panitumumab as first-line treatment of patients with liver-only metastatic KRAS wild-type colorectal cancer.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2096992 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2016-05-05 | E-MTAB-3548 | biostudies-arrayexpress
| 2107060 | ecrin-mdr-crc
| 2156647 | ecrin-mdr-crc
| S-EPMC4786359 | biostudies-literature
| 2063797 | ecrin-mdr-crc
| 2079859 | ecrin-mdr-crc
| 2076606 | ecrin-mdr-crc
| 2071139 | ecrin-mdr-crc
| 2186633 | ecrin-mdr-crc
| 2109056 | ecrin-mdr-crc